| __timestamp | Alnylam Pharmaceuticals, Inc. | Dynavax Technologies Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 190249000 | 84580000 |
| Thursday, January 1, 2015 | 276495000 | 86943000 |
| Friday, January 1, 2016 | 382392000 | 84493000 |
| Sunday, January 1, 2017 | 390635000 | 64988000 |
| Monday, January 1, 2018 | 505420000 | 74951000 |
| Tuesday, January 1, 2019 | 655114000 | 62331000 |
| Wednesday, January 1, 2020 | 654819000 | 28607000 |
| Friday, January 1, 2021 | 792156000 | 32228000 |
| Saturday, January 1, 2022 | 883015000 | 46600000 |
| Sunday, January 1, 2023 | 1004415000 | 54886000 |
| Monday, January 1, 2024 | 1126232000 |
In pursuit of knowledge
In the ever-evolving world of biotechnology, research and development (R&D) investments are the lifeblood of innovation. Over the past decade, Alnylam Pharmaceuticals, Inc. and Dynavax Technologies Corporation have demonstrated contrasting trajectories in their R&D spending. Alnylam's commitment to innovation is evident, with a staggering 428% increase in R&D expenses from 2014 to 2023. This growth underscores their dedication to pioneering RNA interference therapeutics. In contrast, Dynavax's R&D investments have seen a more modest fluctuation, peaking in 2015 and gradually declining thereafter. By 2023, Alnylam's R&D spending was nearly 18 times that of Dynavax, highlighting a strategic divergence in their approaches to innovation. This data not only reflects the companies' priorities but also offers insights into their future potential in the competitive biotech landscape.
Comparing Innovation Spending: Novo Nordisk A/S and Dynavax Technologies Corporation
Analyzing R&D Budgets: Novartis AG vs Dynavax Technologies Corporation
Research and Development: Comparing Key Metrics for Amgen Inc. and Alnylam Pharmaceuticals, Inc.
Analyzing R&D Budgets: Zoetis Inc. vs Dynavax Technologies Corporation
Who Prioritizes Innovation? R&D Spending Compared for argenx SE and Alnylam Pharmaceuticals, Inc.
Analyzing R&D Budgets: Alnylam Pharmaceuticals, Inc. vs Genmab A/S
Analyzing R&D Budgets: Alnylam Pharmaceuticals, Inc. vs Bio-Techne Corporation
R&D Spending Showdown: Alnylam Pharmaceuticals, Inc. vs Ascendis Pharma A/S
Neurocrine Biosciences, Inc. vs Dynavax Technologies Corporation: Strategic Focus on R&D Spending
Comparing Innovation Spending: Ionis Pharmaceuticals, Inc. and Dynavax Technologies Corporation
Comparing Innovation Spending: Vericel Corporation and Dynavax Technologies Corporation
Catalyst Pharmaceuticals, Inc. or Dynavax Technologies Corporation: Who Invests More in Innovation?